Wenkert Deborah 4
4 · Inozyme Pharma, Inc. · Filed Feb 4, 2021
Insider Transaction Report
Form 4
Wenkert Deborah
SVP, CMO
Transactions
- Award
Stock option (Right to Buy)
2021-02-02+100,000→ 100,000 totalExercise: $22.61Exp: 2031-02-01→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]The option was granted on February 2, 2021 and is scheduled to vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the option are scheduled to vest in equal monthly installments over the following three years until the fourth anniversary of the grant date